Open Access

Hashimoto’s Thyroiditis, microcalcification and raised thyrotropin levels within normal range are associated with thyroid cancer

  • Zhi-qiang Ye1,
  • Dian-na Gu2,
  • Hong-ye Hu1,
  • Yi-li Zhou1,
  • Xiao-qu Hu1 and
  • Xiao-hua Zhang1Email author
World Journal of Surgical Oncology201311:56

https://doi.org/10.1186/1477-7819-11-56

Received: 10 November 2012

Accepted: 15 February 2013

Published: 5 March 2013

Abstract

Background

To confirm whether clinical and biochemical parameters or Hashimoto’s thyroiditis (HT) could predict the risks of malignancy among subjects who underwent thyroidectomy, as well as to determine the influence of HT on the biological behavior of papillary thyroid cancer (PTC).

Methods

A total of 2,052 patients who underwent initial thyroidectomy were enrolled between June 2006 and August 2008. Serum free T4, free T3, thyrotropin (TSH), thyroglobulin, thyroglobulin antibody, antimicrosomal antibody, tumor-associated status, and thyroid disorders were documented.

Results

Binary logistic regression analysis was performed to define the risk predictors for thyroid cancer. Finally, calcification, HT, TSH, and age, were entered into the multivariate model. Multivariate logistic regression analysis revealed the risk of thyroid cancer increases in parallel with TSH concentration within normal range, and the risk for malignancy significantly increased with serum TSH 1.97–4.94 mIU/L, compared with TSH less than 0.35 mIU/L (OR = 1.951, 95% CI = 1.201–3.171, P = 0.007). Increased risks of thyroid cancer were also detected among the patients with HT (OR = 3.732, 95% CI = 2.563–5.435), and microcalcification (OR = 14.486, 95% CI = 11.374–18.449). The effects of HT on the aggressiveness of PTC were not observed in extrathyroidal invasion (P = 0.347), capsular infiltration (P = 0.345), angioinvasion (P = 0.512), and lymph node metastases (P = 0.634).

Conclusions

The risk of malignancy increases in patients with higher level TSH within normal range, as well as the presence of HT and microcalcification. No evidence suggests that coexistent HT alleviates the aggressiveness of PTC.

Keywords

Thyroid cancer Thyroiditis Papillary thyroid cancer Thyrotropin

Background

Thyroid cancer is the most frequent endocrine malignancy, accounting for approximately 1% of all malignant tumors in the United States [1]. However, a recent study [2] by the Office of Cancer Prevention and Treatment indicates that thyroid cancer represents 5.90% of all new malignant diseases in one district of Wenzhou (a coastal city in Southeast China, with a referral population of 7,558,000). The detection rate of thyroid nodules is higher than before because of high-resolution ultrasound [3]. In order to identify patients with thyroid cancer who require early intervention, many predisposing factors for malignancy have been recognized, including young age (<20 years old) or older age (>70 years old), male gender, large (>4 cm) or rapidly growing nodules, and history of radiation exposure, calcification and thyroglobulin (Tg) [47]. The role of thyroid-stimulating hormone (TSH) in the growth and development of thyroid cancer has long been known [8]. Recently, Boelaert et al. [9] proposed that the TSH level at presentation is a novel predictor of malignancy in patients with thyroid nodules. Another report indicated that higher TSH levels were associated with greater risks of differentiated thyroid cancer and advanced tumor stage [10]. The findings above need to be verified further.

Hashimoto’s thyroiditis (HT) is an autoimmune disease characterized by widespread lymphocyte infiltration, fibrosis, and parenchymal atrophy [11]. Historically, HT was thought to be associated with malignant lymphoma. However, Dailey et al. in 1955 first reported an increased association between HT and papillary thyroid cancer (PTC) [12]. The coexistence of these two diseases has been variously reported to range from 0.5% to 38.0% [11, 1318]. A few studies have proposed HT as a risk factor for thyroid cancer [12, 16, 18, 19], whereas others have reported a negative correlation between the two diseases [10, 13, 15]. Nowadays, the causal association between these diseases remains controversial, and few papers have discussed whether HT influences the clinical and pathologic features of thyroid cancer.

Therefore, the current study investigates which clinical features or biochemical criteria predict the likelihood of thyroid malignancy in patients with thyroid nodules, thereby identifying those at greatest risk of harboring thyroid cancer. Other objectives of the current study are to determine the following: 1) the relative incidence of HT and PTC among patients undergoing thyroidectomy, and 2) the possible influence of HT on the clinical behavior and neoplastic aggressiveness of PTC.

Methods

A total of 2,052 patients (1,645 female and 407 male) with thyroid nodules, in whom malignancy was suspected under fine-needle aspiration (FNA) or ultrasonography, or who had rapidly growing nodules or nodules fixed to adjacent structures, and who underwent initial thyroidectomy in the First Affiliated Hospital of Wenzhou Medical College, were retrospectively recruited from June 2006 to August 2008. However, some female patients underwent surgery because of cosmetic problems or anxiety about the effects on their quality of life. The majority of the patients received treatment for thyroid cancer according to the accepted protocol, which involves total or near-total thyroidectomy, followed by thyroid hormone suppression. Cervical lymph node dissection or sentinel lymph node biopsy was performed routinely during thyroid cancer’s operation. Others underwent resection of the whole or partial lobes of the thyroid gland.

The diagnosis was confirmed either on reevaluation of histopathology sections when available, or on reviewing the previous pathology reports. The histologic type of thyroid cancer was assessed by two senior pathologists according to the World Health Organization criteria and classified as PTC in 1004 patients (98.05%), including two with coexisting PTC and malignant lymphoma, follicular thyroid cancer (FTC) in four patients (0.39%), medullary thyroid cancer in twelve patients (1.17%), and anaplastic thyroid cancer in four patients (0.39%). Patients who were characterized by the presence of diffuse lymphocytic and plasma cell infiltration, oxyphilic cells, and lymphoid follicles with reactive germinal centers, were defined as having HT. Whereas patients with lymphocytic infiltration immediately surrounding the malignant tumor (but without other lobe involvement) were considered as having thyroid cancer alone because the surrounding inflammation may represent an immune response to the host tumor [20].

In addition to the demographic data (age and gender), data on the thyroid-associated parameters [serum free T4 (fT4), free T3 (fT3), TSH, Tg, and thyroglobulin antibody (TgAb), antimicrosomal antibody (TMAb)], tumor-associated status (tumor size, number and region of positive lymph nodes, and metastasis (TNM) stage), and thyroid disorders (presence or absence of HT, Graves disease, follicular adenoma, or malignant lymphoma) were obtained from a review of the medical records from the Patient Information Inquiry System. The normal ranges of serum fT3, fT4, TSH, Tg, TgAb, and TMAb were 3.67 to 10.43 pmol/L, 7.5 to 21.1 pmol/L, 0.35 to 4.94 mIU/L, 4.14 to 14.46 ng/ml, 0.0% to 30.0%, and 0.0% to 20.0%, respectively. We had free thyroid hormones, TSH, Tg, TgAb, and TMAb measured simultaneously with surgery. However, the measurement results of patients known to have taken thyroid medication were excluded. This research was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical College.

The final diagnostic outcome was defined as the presence or absence of thyroid cancer. Data were analyzed using Statistical Package for Social Science (SPSS) version 13.0. The odds ratio (OR) in multivariate logistic regression analysis, with the relative 95% CI was calculated to assess the relevance of thyroid-associated clinical or biochemical conditions to predict the final diagnostic outcome. Confounding factors, including age, gender, and thyroid disorders, were investigated statistically. Comparisons of frequency distributions and numerical variable data were performed using the chi-square (χ2) test. Observed differences were considered statistically significant if the probability of chance occurrence was less than 0.05.

Results

The clinical and biochemical features of patients with and without thyroid cancer were compared. Of the 1,024 patients with thyroid cancer, female patients (n = 843) accounted for the majority (female/male ratio = 4.66/1.00). The age distribution (range 10 to 84 years, mean 45.0 ± SD 12.1 years) revealed a predominance in the 30 to 44-year-old age group (n = 449 patients, 43.8%) with thyroid cancer. However, the high tumor incidence in the 45 to 60-year-old age group (n = 370 patients, 36.1%) should not be neglected. Comparison between the two groups highlighted a statistically significant difference in gender (χ2 = 5.990, P = 0.014), age (χ2 = 13.588, P = 0.018) (Table 1). To avoid the interference of several extreme values, fT3, fT4, TSH, Tg, TgAb, and TMAb were treated as categorical variables in the analysis. Significant differences were detected when the following values were compared: TSH (χ2 = 20.160, P <0.001), TgAb (χ2 = 14.142, P <0.001) and TMAb (χ2 = 15.026, P <0.001) but not fT3 (χ2 = 4.784, P = 0.306), fT4 (χ2 = 4.548, P = 0.337), and Tg (χ2 = 3.431, P = 0.180) among patients with and without thyroid cancer (Table 2). Moreover, the presence of HT was associated with thyroid cancer (χ2 = 67.421, P <0.001). Regarding calcification of the thyroid nodules, the incidence of microcalcification was higher in patients with thyroid cancer than in the controls (71.4% vs 16.2%, χ2 = 633.792, P <0.001). However, the prevalence of thyroid cancer was similar in patients with solitary nodules and patients with multiple nodules (χ2 = 1.456, P = 0.228) (Table 1).
Table 1

Comparison of characteristics of patients with and without thyroid cancer

Characteristics

Thyroid cancer

P-valuea

Present (n = 1,024)

Absent (n = 1,028)

Gender

  

0.014*

Male

181 (17.7)

226 (22.0)

 

Female

843 (82.3)

802 (78.0)

 

Age, yr

  

0.018*

0 ~ 14

3 (0.3)

5 (0.5)

 

15~29

85 (8.3)

89 (8.7)

 

30~44

449 (43.8)

382 (37.2)

 

45~59

370 (36.1)

411 (40.0)

 

60~74

103 (10.1)

133 (12.9)

 

75~89

14 (1.4)

8 (0.8)

 

Nodular type

  

0.228

Diffuse/multinodular goiter

651 (63.6)

627 (61.0)

 

Solitary nodules

373 (36.4)

401 (39.0)

 

Calcification

   

Coarse calcifications

  

0.727

Absent

886 (86.5)

884 (86.0)

 

Present

138 (13.5)

144 (14.0)

 

Microcalcification

  

<0.001*

Absent

293 (28.6)

861 (83.8)

 

Present

731 (71.4)

167 (16.2)

 

HT

  

<0.001*

Absent

836 (81.6)

962 (93.6)

 

Present

188 (18.4)

66 (6.4)

 

Results are presented as number (%) of patients. aCalculated using chi-square test; *statistically significant (P <0.05). HT, Hashimoto’s thyroiditis.

Table 2

Comparison of the biochemical features of patients with and without thyroid cancer

Characteristics

Thyroid cancer

P-valuea

Present (n = 1,024)

Absent (n = 1,028)

The level of thyroid-associated hormone

   

fT3, pmol/Lb

  

0.306

<3.67

82 (9.2)

66 (7.3)

 

3.67 to 4.42

263 (29.6)

287 (31.7)

 

4.43 to 4.97

284 (32.0)

266 (29.4)

 

4.98 to 10.43

258 (29.1)

283 (31.3)

 

>10.43

1 (0.1)

2 (0.2)

 

fT4, pmol/Lb

  

0.337

<7.5

11 (1.2)

5 (0.6)

 

7.5 to 12.83

301 (33.9)

282 (31.2)

 

12.84 to 14.85

281 (31.6)

303 (33.5)

 

14.86 to 21.1

283 (31.9)

299 (33.0)

 

>21.1

12 (1.4)

16 (1.8)

 

TSH, mIU/Lb

  

<0.001*

<0.35

58 (6.1)

84 (8.7)

 

0.35 to 1.17

258 (27.1)

312 (32.4)

 

1.18 to 1.96

273 (28.6)

283 (29.4)

 

1.97 to 4.94

317 (33.3)

247 (25.7)

 

>4.94

47 (4.9)

36 (3.7)

 

Tg, ng/ml

  

0.180

<4.14

131 (34.3)

107 (36.1)

 

4.14 to 14.46

158 (41.4)

103 (34.8)

 

>14.46

93 (24.3)

86 (29.1)

 

Antibodyc (n = 748)

   

TgAb

  

<0.001*

Negative

309 (78.4)

314 (88.7)

 

Positive

85 (21.6)

40 (11.3)

 

TMAb

  

<0.001*

Negative

309 (78.4)

315 (89.0)

 

Positive

85 (21.6)

39 (11.0)

 

Results are presented as number (%) of patients. aCalculated using chi-square test; bpatients with free T3 (fT3), fT4, or thyroid-stimulating hormone (TSH) measurements within the normal range were divided into three tertiles of similar size, respectively; conly 748 patients who had information on thyroglobulin antibody (TGAb) and antimicrosomal antibody (TMAb) were included in the analysis; *statistically significant (P <0.05). Tg, thyroglobulin.

Subsequently, a binary logistic regression analysis was performed to define the risk predictors for thyroid cancer, which simultaneously analyzed gender, age, serum fT3, fT4 and TSH concentration, HT, and calcification. In addition, considering the feedback inhibition regulation of TSH by serum fT3 and fT4 concentrations, the interaction of variables between TSH and/or fT3, and/or fT4 were also taken into account in the analysis. Finally, four variables, namely, calcification, HT, TSH, and age, were entered into the multivariate model via forward stepwise regression (likelihood ratio). An increased risk of thyroid cancer was detected among the patients with HT (OR = 3.732, 95%CI = 2.563–5.435), microcalcification (OR = 14.486, 95%CI = 11.374–18.449). There was significantly increased risk of malignancy in patients with serum TSH of 1.97 to 4.94 mIU/L, compared to patients with TSH below 0.35 mIU/L (OR = 1.951, 95% CI = 1.201–3.171, P = 0.007) (Table 3).
Table 3

Independent risk predictors for diagnosis of thyroid malignancy under multivariate logistic regression analysis (n = 1,789 patients)

Variable

Adjusted odds ratio

95% CI

P-value

Age, yr

  

0.004*

0 ~ 14

1.00

  

15~29

1.217

0.164, 9.032

0.848

30~44

1.544

0.215, 11.092

0.666

45~59

1.188

0.165, 8.550

0.864

60~74

0.724

0.098, 5.321

0.751

75~89

2.852

0.300, 27.138

0.362

TSH, mIU/La

  

0.001*

<0.35

1.00

  

0.35 to 1.17

1.079

0.663, 1.756

0.759

1.18 to 1.96

1.357

0.835, 2.207

0.218

1.97 to 4.94

1.951

1.201, 3.171

0.007*

>4.94

1.235

0.598, 2.550

0.568

HT

   

Absent

1.00

  

Present

3.732

2.563, 5.435

<0.001*

Calcification

   

Coarsecalcifications

1.00

  

Microcalcification

14.486

11.374, 18.449

<0.001*

aPatients with free T3 (fT3), fT4, or TSH measurements within the normal range were divided into tertiles of similar size, respectively. Variables assigned odds ratios of 1.0 were used as the reference for multivariate analysis. *Statistically significant (P <0.05).

The patients suffering from PTC (n = 1004, 98.05%) were selected and divided into patients with HT (group I) and patients without HT (group II) based on the final histologic examination. Tables 4 and 5 show the clinical and pathologic features of the two groups; 18.63% of the patients with PTC had concurrent HT, which was more frequent than in the benign group (P <0.001). Moreover, the female patients constituted an overwhelming 97.3% (n = 182) of the patients with coexisting PTC and HT. The mean age at initial thyroidectomy was similar between the groups (χ2 = 7.298, P = 0.063), as well as thyroid-associated disorders (χ2 = 3.322, P = 0.325) (Table 4). Furthermore, the tumor size (χ2 = 2.975, P = 0.209), frequency of occult PTC (χ2 = 2.872, P = 0.090), extrathyroidal invasion (χ2 = 0.885, P = 0.347), capsular infiltration (χ2 = 0.891, P = 0.345), angioinvasion (χ2 = 0.429, P = 0.512), and lymph node metastases (χ2 = 0.227, P = 0.634) did not differ between patients with and without HT. No distant metastasis was observed in the two groups. Although the majority of positive lymph nodes (58.3%) in patients with HT were distributed in level VI (classification references [21]) and a higher proportion was observed in group I with stage I (85.6%), the difference was not significant compared with group II (χ2 = 4.703, P = 0.427; χ2 = 0.540, P = 0.910, respectively), in other words, the pathologic TNM (pTNM) classification in the two groups were similar (shown in Table 5).
Table 4

Clinical features of patients with papillary thyroid cancer by group in patients with and without Hashimoto’s thyroiditis (HT)

Characteristics

Group I

Group II

χ2

P-value

(with HT)

(without HT)

n = 187

n = 817

Age, yr

  

7.298

0.063

<30

23 (12.3)

65 (8.0)

  

30~44

76 (40.6)

362 (44.3)

  

45~59

74 (39.6)

291 (35.6)

  

>60

14 (7.5)

99 (12.1)

  

Gender

  

35.082

<0.001*

Male

5 (2.7)

171 (20.9)

  

Female

182 (97.3)

646 (79.1)

  

Thyroid-associated disorders

  

3.322

0.325

Nodular goiter

56 (81.2)

258 (82.2)

  

Follicular adenoma

8 (11.6)

45 (14.3)

  

Graves disease

4 (5.8)

10 (3.2)

  

Malignant lymphoma

1 (1.4)

1 (0.3)

  

Results are presented as number (%) of patients. *Statistically significant (P < 0.05).

Table 5

Pathologic features of patients with papillary thyroid cancer (PTC) by group in patients with and without Hashimoto’s thyroiditis (HT)

Characteristics

Group I

Group II

χ2

P-value

(with HT)

(without HT)

n = 187

n = 817

Pathological TNM staging

  

0.540

0.910

I

160 (85.6)

687 (84.1)

  

II

4 (2.1)

25 (3.1)

  

III

15 (8.0)

70 (8.6)

  

IV

8 (4.3)

35 (4.3)

  

Tumor size

  

2.975

0.209

≤1 cm

126 (67.4)

496 (60.7)

  

1 to 4 cm

59 (31.6)

304 (37.2)

  

>4 cm

2 (1.1)

17 (2.1)

  

Frequency of occult PTC

  

2.872

0.090

Absent

61 (32.6)

321(39.3)

  

Present

126 (67.4)

496 (60.7)

  

Lymph nodes metastases

  

0.227

0.634

Absent

129 (69.0)

578 (70.7)

  

Present

58 (31.0)

239 (29.3)

  

Distribution of positive lymph nodes

  

4.703

0.427

Level VI

49 (58.3)

217 (54.5)

  

Level II

9 (10.7)

33 (8.3)

  

Level III

9 (10.7)

48 (12.1)

  

Level IV

10 (11.9)

47 (11.8)

  

Level V

6 (7.1)

52 (13.1)

  

Level I

1 (1.2)

1 (0.3)

  

Extrathyroidal invasion

  

0.885

0.347

Absent

184 (98.4)

794 (97.2)

  

Present

3 (1.6)

23 (2.8)

  

Capsular infiltration

  

0.891

0.345

Absent

159 (85.0)

671 (82.1)

  

Present

28 (15.0)

146 (17.9)

  

Vascular invasion

  

0.429

0.512

Absent

186 (99.5)

815 (99.8)

  

Present

1 (0.5)

2 (0.2)

  

Distant metastases

0

0

  

Results for Groups I and II are presented as number (%) of patients. *Statistically significant (P <0.05).

Discussion

As shown in the current study, the peak incidence of thyroid cancer in Wenzhou occurs in the 30 to 44-year-old age group. Moreover, when the association between gender and thyroid cancer was assessed, significantly increased rates of malignancy were detected among the female patients (82.3%) (χ2 = 5.990, P = 0.014). However, further logistic regression analysis did not identify gender as an independent risk predictor. These results may challenge a previously recognized view of an increased risk of underlying malignancies in male patients [5, 9, 22, 23]. Furthermore, the patient age was demonstrated as a risk predictor for malignancy. Increased adjusted ORs for thyroid cancer were observed in the older age group (75 years) in accordance with previous reports [22, 24], although no significant difference was observed compared with the young age group (<15 years, P = 0.362).

The risk of thyroid cancer has been shown to increase with serum TSH concentrations, and even within normal ranges, higher TSH levels are associated with a higher incidence and more advanced stage of thyroid malignant tumor [9, 10, 24, 25]. Serum TSH has a tropic effect on thyroid nodules and suppression of TSH concentration by administration of exogenous thyroxine may interfere with the growth of established nodules, as well as the formation of new thyroid nodules [2629]. TSH suppression is also associated with a decreased frequency of PTC [30].

We demonstrated that the risk of thyroid cancer increased in parallel with the serum TSH concentration within the normal range at presentation. This observation is supported by a previous study [24]. In our study, serum TSH concentration (>4.94 mIU/L) was not associated with the greatest risk of thyroid cancer, which is inconsistent with other studies [8, 9]. We have no vigorous explanation for this inconsistency. One reason may be that the sample size of the group with serum TSH concentrations >4.94 mIU/L was smaller than the other groups. In addition, the mechanism of TSH on thyroid disease may differ between populations. Furthermore, several arguments weaken the role of TSH in the development or progression of malignant thyroid tumors: 1) TSH receptor mutations in regions functionally associated with increased signal transduction do not often occur in malignant thyroid tumors [31]; 2) other growth factors such as insulin-like growth factor-I (IGF-I) have been demonstrated to have a more important role in the growth of thyroid cancer in in vitro studies [32, 33], and TSH needs cooperation with insulin/IGF-1 to educe its proliferative effects [34]; 3) Shi et al. [35] reported that the relationship between TSH receptor mRNA levels and the aggressiveness of cancer was inversed; 4) thyroid cancer occurs in patients with serum TSH concentrations suppressed by hyperfunctioning nodules in the contralateral lobe [36]; 5) a recent study showed that patients carrying one of two alleles associated with an increased risk of differentiated thyroid cancer have lower serum TSH concentrations [37].

Taken together, TSH is unlikely to act versatilely in cancer development. These findings indicate that serum TSH concentration can be used as an adjunct biochemical predictor of thyroid cancer. However, this requires further investigation.

In contrast to previous studies [7, 38] that reported that Tg levels were significantly higher in patients with thyroid cancer than in those with benign disorders, no significant difference in Tg concentration was observed in patients with malignancy. Limited to the current measurement, whether preoperative serum Tg measurement helps differentiate benign from malignant thyroid disorders needs further verification. Ultrasonography cannot reliably distinguish benign from malignant lesions [39]. The current study demonstrates similar incidences of malignancy between patients with solitary nodules and those with diffuse or multinodular lesions, as reported by ultrasonography, although others found that the presence of solitary nodules found by palpation is associated with increased malignancy rates [5, 9, 40, 41]. In addition, a higher risk of malignancy was detected in patients with microcalcification (OR = 14.486, P <0.001, Table 3), which is consistent with recent investigations in patients evaluated through ultrasonography [42, 43]. Nevertheless, approximately 13.5% of patients with thyroid cancer (n = 138) were confirmed to have coexisting coarse calcifications. Accordingly, ultrasonographic findings, such as solitary nodules or multinodular types, as well as microcalcifications or coarse calcifications, should not prevent further evaluation of benign or malignant lesions.

In the present study, a vast majority of thyroid malignancies were PTC (98.05%) and HT was found to coincide highly with PTC (18.63%). Moreover, further regression analysis identified the presence of HT as an independent risk predictor for malignancy (OR = 3.732, P <0.001, Table 3). These data confirm the large American dataset from Dr. Skahen’s report of 1955 [12]. Subsequent studies showed a similar association between PTC and HT. Although according to previous reports, hypothyroidism induced by HT could induce high serum TSH concentration, which may enhance the proliferative activity of follicular epithelia and result in the development of PTC [44], the oncogenic effect that causes PTC in patients with HT are still unknown. According to Harach et al. [45], iodine intake may play a role in the tumorigenesis of thyroiditis. Although Wenzhou is an iodine-sufficient area, determining the correlation between HT and PTC in terms of iodine intake is difficult because no information on iodine intake was available in the majority of patients studied. Some molecular mechanisms, such as the PI3K/Akt or RET/RAS/ERK pathways may also contribute to tumorigenesis [20, 46]. At present, no evidence suggests that HT is a premalignant lesion for PTC. Furthermore, in contrast to previous studies that reported that the presence of HT in PTC is associated with better prognosis, lower recurrence, and a less aggressive disorder than cases without HT [4749], the current results did not find that HT has a protective effect on tumor aggressiveness in patients with PTC, which is consistent with the recent reports by Del Rio et al. [50]. Recently, Kim et al. reported that HT was positively associated with multifocality and smaller size but not with extrathyroidal invasion, nodal metastasis, or TNM stage [51]. These divergences may be due, at least in part, to differences in patient selection (this retrospective study only included patients undergoing thyroidectomy, thus, a percentage of patients with HT that are treated conservatively may have been omitted), or to indications for thyroidectomy, inclusion of different histologic types (others included PTC as well as FTC), or varying definitions of thyroiditis. Nevertheless, the current results indicate that the presence of HT represents an increased risk of developing thyroid cancer, particularly PTC, but may have a minimum effect on the aggressiveness of the malignancy.

Conclusions

In conclusion, the risk of thyroid malignancy increases with the presence of HT and microcalcification as evaluated by ultrasonography. Raised TSH levels within the normal range are also independently associated with the likelihood of thyroid malignancy. Coexisting HT in PTC does not have a significant effect on the biologic behavior of PTC. Based on the current findings, because the study was retrospective, we do not advocate a more aggressive role for surgical intervention for patients with HT, microcalcification, or even high TSH levels. Prospective large-scale studies are required to verify or establish the potentially important factors for predicting thyroid malignancy, and the follow-up of the patients with HT in PTC should be done to verify long-term prognosis in clinical practice.

Consent

Written informed consent was obtained from the patient for publication of this report and any accompanying images.

Abbreviations

HT: 

Hashimoto’s thyroiditis

PTC: 

Papillary thyroid cancer

TSH: 

Thyrotropin

TSH: 

Thyroid stimulating hormone

Tg: 

Thyroglobulin

FNA: 

Fine-needle aspiration

FTC: 

Follicular thyroid cancer

fT4: 

free T4

fT3: 

free T3

TgAb: 

Thyroglobulin antibody

TMAb: 

antimicrosomal antibody

OR: 

Odds ratio.

Declarations

Acknowledgements

We thank all of the pathologists at The First Affiliated Hospital of Wenzhou Medical College for their assistance with the pathologic analysis, as well as all of our colleagues from the Medical Record Room at our hospital. Without their efforts, this article would not be possible. This work was supported by the National 863 project of China (NO.2012AA02A210).

Authors’ Affiliations

(1)
Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical College
(2)
Department of Infection and Liver Diseases, The First Affiliated Hospital of Wenzhou Medical College

References

  1. Sherman SI: Thyroid carcinoma. Lancet. 2003, 361: 501-511. 10.1016/S0140-6736(03)12488-9.View ArticlePubMedGoogle Scholar
  2. Zheng W, Zhang Z: An analysis of cancer incidence in 2005 in Lucheng District, Wenzhou City, Zhejiang Province. Bulletin of Chinese Cancer. 2007, 16: 306-308.Google Scholar
  3. Marqusee E, Benson CB, Frates MC, Doubilet PM, Larsen PR, Cibas ES, Mandel SJ: Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med. 2000, 133: 696-700. 10.7326/0003-4819-133-9-200011070-00011.View ArticlePubMedGoogle Scholar
  4. Shibata Y, Yamashita S, Masyakin VB, Panasyuk GD, Nagataki S: 15 years after Chernobyl: new evidence of thyroid cancer. Lancet. 2001, 358: 1965-1966. 10.1016/S0140-6736(01)06971-9.View ArticlePubMedGoogle Scholar
  5. Hegedus L, Bonnema SJ, Bennedbaek FN: Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003, 24: 102-132. 10.1210/er.2002-0016.View ArticlePubMedGoogle Scholar
  6. Yeung MJ, Serpell JW: Management of the solitary thyroid nodule. Oncologist. 2008, 13: 105-112. 10.1634/theoncologist.2007-0212.View ArticlePubMedGoogle Scholar
  7. Christensen SB, Bondeson L, Ericsson UB, Lindholm K: Prediction of malignancy in the solitary thyroid nodule by physical examination, thyroid scan, fine-needle biopsy and serum thyroglobulin. A prospective study of 100 surgically treated patients. Acta Chir Scand. 1984, 150: 433-439.PubMedGoogle Scholar
  8. Stocker DJ, Burch HB: Thyroid cancer yield in patients with Graves' disease. Minerva Endocrinol. 2003, 28: 205-212.PubMedGoogle Scholar
  9. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA: Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006, 91: 4295-4301. 10.1210/jc.2006-0527.View ArticlePubMedGoogle Scholar
  10. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H: Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008, 93: 809-814.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Cipolla C, Sandonato L, Graceffa G, Fricano S, Torcivia A, Vieni S, Latteri S, Latteri MA: Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005, 71: 874-878.PubMedGoogle Scholar
  12. Dailey ME, Lindsay S, Skahen R: Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA. 1955, 70: 291-297.Google Scholar
  13. Crile G: Struma lymphomatosa and carcinoma of the thyroid. Surg Gynecol Obstet. 1978, 147: 350-352.PubMedGoogle Scholar
  14. Crile G, Hazard JB: Incidence of cancer in struma lymphomatosa. Surg Gynecol Obstet. 1962, 115: 101-103.PubMedGoogle Scholar
  15. Holm LE, Blomgren H, Lowhagen T: Cancer risks in patients with chronic lymphocytic thyroiditis. N Eng J Med. 1985, 312: 601-604. 10.1056/NEJM198503073121001.View ArticleGoogle Scholar
  16. Ott RA, McCall AR, McHenry C, Jarosz H, Armin A, Lawrence AM, Paloyan E: The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Am Surg. 1987, 53: 442-445.PubMedGoogle Scholar
  17. Shands WC: Carcinoma of the thyroid in association with struma lymphomatosa (Hashimoto's disease). Ann Surg. 1960, 151: 675-682. 10.1097/00000658-196005000-00008.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP: Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery. 1999, 126: 1070-1076. 10.1067/msy.2099.101431. discussion 1076–1077View ArticlePubMedGoogle Scholar
  19. Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, Scutari M, Basolo F, Di Coscio G, Grasso L: Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 2011, 18: 429-437. 10.1530/ERC-11-0028.View ArticlePubMedGoogle Scholar
  20. Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM: Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007, 204: 764-773. 10.1016/j.jamcollsurg.2006.12.037. discussion 773–765PubMed CentralView ArticlePubMedGoogle Scholar
  21. Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA: Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008, 134: 536-538. 10.1001/archotol.134.5.536.View ArticlePubMedGoogle Scholar
  22. Hegedus L: Clinical practice. The thyroid nodule. N Eng J Med. 2004, 351: 1764-1771. 10.1056/NEJMcp031436.View ArticleGoogle Scholar
  23. Mazzaferri EL: Management of a solitary thyroid nodule. N Eng J Med. 1993, 328: 553-559. 10.1056/NEJM199302253280807.View ArticleGoogle Scholar
  24. Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D, Flaris N, Leontsini M, Kourtis A, Avramidis A: Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol. 2008, 134: 953-960. 10.1007/s00432-008-0373-7.View ArticlePubMedGoogle Scholar
  25. Jonklaas J, Nsouli-Maktabi H, Soldin SJ: Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid. 2008, 18: 943-952. 10.1089/thy.2008.0061.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Gharib H: Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr Pract. 2004, 10: 31-39.View ArticlePubMedGoogle Scholar
  27. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbrini R, Pacella CM: Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab. 1998, 83: 780-783. 10.1210/jc.83.3.780.View ArticlePubMedGoogle Scholar
  28. Vermiglio F, Lo Presti VP, Violi MA, Moleti M, Castagna MG, Finocchiaro MD, Mattina F, Mandolfino M, Zimbaro G, Trimarchi F: Changes in both size and cytological features of thyroid nodule after levothyroxine treatment. Clin Endocrinol. 2003, 59: 347-353. 10.1046/j.1365-2265.2003.01854.x.View ArticleGoogle Scholar
  29. Zelmanovitz F, Genro S, Gross JL: Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab. 1998, 83: 3881-3885. 10.1210/jc.83.11.3881.PubMedGoogle Scholar
  30. Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Coscio G, Miccoli P, Grasso L, Pinchera A, Vitti P: L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. Endocr Relat Cancer. 2010, 17: 231-239. 10.1677/ERC-09-0251.View ArticlePubMedGoogle Scholar
  31. Matsuo K, Friedman E, Gejman PV, Fagin JA: The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. J Clin Endocrinol Metab. 1993, 76: 1446-1451. 10.1210/jc.76.6.1446.PubMedGoogle Scholar
  32. Derwahl M, Broecker M, Kraiem Z: Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab. 1999, 84: 829-834. 10.1210/jc.84.3.829.PubMedGoogle Scholar
  33. Mazzaferri EL: Thyroid cancer and Graves' disease: the controversy ten years later. Endocr Pract. 2000, 6: 221-225. 10.4158/EP.6.2.221.View ArticlePubMedGoogle Scholar
  34. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP: Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev. 2001, 22: 631-656. 10.1210/er.22.5.631.View ArticlePubMedGoogle Scholar
  35. Shi Y, Zou M, Farid NR: Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis. Clin Endocrinol. 1993, 39: 269-274. 10.1111/j.1365-2265.1993.tb02365.x.View ArticleGoogle Scholar
  36. Satta MA, De Rosa G, Testa A, Maussier ML, Valenza V, Rabitti C, Saletnich I, D'Ugo D, Picciocchi A: Thyroid cancer in suppressed contralateral lobe of patients with hot thyroid nodule. Eur J Cancer. 1993, 29A: 1190-1192.View ArticlePubMedGoogle Scholar
  37. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT, He H, Blondal T, Geller F, Jakobsdottir M: Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet. 2009, 41: 460-464. 10.1038/ng.339.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Spencer CA: Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. Endocr Pract. 2000, 6: 481-484.PubMedGoogle Scholar
  39. Hegedus L: Thyroid ultrasound. Endocrinol Metab Clin North Am. 2001, 30: 339-360. 10.1016/S0889-8529(05)70190-0. viii-ixView ArticlePubMedGoogle Scholar
  40. Franklyn JA, Daykin J, Young J, Oates GD, Sheppard MC: Fine needle aspiration cytology in diffuse or multinodular goitre compared with solitary thyroid nodules. BMJ. 1993, 307: 240-10.1136/bmj.307.6898.240.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Mazzaferri EL, Santos ET Dl, Rofagha-Keyhani S: Solitary thyroid nodule: diagnosis and management. MCNA. 1988, 72: 1177-1211.Google Scholar
  42. Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD, Larsen PR, Marqusee E, Alexander EK: Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006, 91: 3411-3417. 10.1210/jc.2006-0690.View ArticlePubMedGoogle Scholar
  43. Wang N, Xu Y, Ge C, Guo R, Guo K: Association of sonographically detected calcification with thyroid carcinoma. Head Neck. 2006, 28: 1077-1083. 10.1002/hed.20481.View ArticlePubMedGoogle Scholar
  44. Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR: Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans. Cancer. 1995, 76: 2312-2318. 10.1002/1097-0142(19951201)76:11<2312::AID-CNCR2820761120>3.0.CO;2-H.View ArticlePubMedGoogle Scholar
  45. Harach HR, Ceballos GA: Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model. Endocr Pathol. 2008, 19: 209-220. 10.1007/s12022-008-9038-y.View ArticlePubMedGoogle Scholar
  46. Kang DY, Kim KH, Kim JM, Kim SH, Kim JY, Baik HW, Kim YS: High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid. 2007, 17: 1031-1038. 10.1089/thy.2007.0035.View ArticlePubMedGoogle Scholar
  47. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, Uchino S, Toda M, Sasaki A, Daa T, Nakayama I: Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid. 1998, 8: 197-202. 10.1089/thy.1998.8.197.View ArticlePubMedGoogle Scholar
  48. Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP: Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 1999, 84: 458-463. 10.1210/jc.84.2.458.View ArticlePubMedGoogle Scholar
  49. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, Matsuzuka F, Kakudoh K, Kuma K, Tamai H: The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab. 1995, 80: 3421-3424. 10.1210/jc.80.12.3421.PubMedGoogle Scholar
  50. Del Rio P, Cataldo S, Sommaruga L, Concione L, Arcuri MF, Sianesi M: The association between papillary carcinoma and chronic lymphocytic thyroiditis: does it modify the prognosis of cancer?. Minerva Endocrinol. 2008, 33: 1-5.PubMedGoogle Scholar
  51. Kim KW, Park YJ, Kim EH, Park SY, Park Do J, Ahn SH, Jang HC, Cho BY: Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck. 2011, 33: 691-695. 10.1002/hed.21518.View ArticlePubMedGoogle Scholar

Copyright

© Ye et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement